Phaseline

Companies › Orna Therapeutics

Orna Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Other; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ORN252
circular RNA encoding anti-CD19 CAR protein in lipid nanoparticle
CD19Phase 1Healthy Volunteers - Male and FemaleDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07439796ORN252Phase 1Healthy Volunteers - Male and FemaleOtherDec 2026

Targets

CD19 (1)

Companies with the same targets

Gilead Sciences Bristol-Myers Squibb Chongqing Precision Biotech Allogene Therapeutics Miltenyi Biomedicine Amgen AstraZeneca Beijing Yongtai Ruike Biotechnology Company Shanghai Ming Ju Biotechnology iCell Gene Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.